Intravesical Evans Bacille Calmette-Guérin in the Treatment of Carcinomain situ

Publisher Website
Google Scholar
Abstract
We report our experience in the treatment of carcinoma in situ of the urinary bladder using Evans strain Bacille Calmette-Gerin (BCG). The mean period of follow-up was 30 months; 18 patients received intravesical therapy and 16 of these were evaluable. They received 8 weekly instillations of 60 mg Evans strain BCG in 50 ml of saline. No intradermal BCG was given. The response rate was 93.75% at 3 months; this declined to 57% at 2 years. The complications of therapy were frequent but milk. Seven patients failed to complete the course. These results were comparable to those obtained with other strains of Bacille Calmette-Guerin.